Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Rating of "Reduce" from Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have earned an average recommendation of "Reduce" from the eight analysts that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $23.00.

Several research firms have recently commented on IART. Citigroup increased their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a report on Tuesday, November 5th. Bank of America cut their price objective on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research report on Monday, October 7th. Truist Financial decreased their target price on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target for the company. Finally, BTIG Research upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th.

Integra LifeSciences Stock Up 1.0 %

IART traded up $0.24 during trading hours on Friday, hitting $24.10. 415,162 shares of the company's stock were exchanged, compared to its average volume of 789,292. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The stock's 50-day moving average is $21.44 and its two-hundred day moving average is $23.90.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $380.80 million during the quarter, compared to analysts' expectations of $375.81 million. During the same quarter last year, the company earned $0.76 EPS. Integra LifeSciences's revenue for the quarter was down .4% compared to the same quarter last year. As a group, equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its holdings in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after acquiring an additional 444 shares during the period. CWM LLC lifted its stake in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after purchasing an additional 425 shares during the last quarter. KBC Group NV boosted its holdings in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after purchasing an additional 1,120 shares in the last quarter. Northwest Investment Counselors LLC acquired a new stake in Integra LifeSciences in the third quarter valued at about $73,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences in the 2nd quarter valued at approximately $114,000. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.